Cent

Covance ends 2005 on the upswing

Covance ends 2005 on the upswing

By Kirsty Barnes

Covance closed 2005 on a high after net revenues climbed 16.9 per
cent from 2004 to reach $1.19 bn (€1 bn). The current trend towards
outsourcing R&D, coupled with increased productivity and repeat
business has fuelled the company's...

R&D spending per NME declines

R&D spending per NME declines

According to a recent survey, the pharma industry spent an
estimated $1.25 billion for each new molecular entity (NME)
approved by the FDA in 2004. The figure represents the second
consecutive year in which this figure has declined...

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All